Biogen Stock Is Down on a Report That Few Have Received Its New Alzheimer’s Therapy
By Josh Nathan-Kazis
Sept. 22, 2021 10:04 am ET
Investors’ deepest worries about Biogen‘s controversial Alzheimer’s therapy seemed to be coming true early Wednesday. Health-care news site STAT revealed that only around 100 patients had received Biogen‘s newly approved Alzheimer’s disease therapy Aduhelm as of Sept. 11.
Investors had expected the launch to go slowly, and Biogen (ticker: BIIB) has tried to limit expectations in recent months. Still, the STAT report suggests that the rollout is going even worse than investors had thought.
>>403
Biogen Stock Is Down on a Report That Few Have Received Its New Alzheimer’s Therapy
By Josh Nathan-Kazis
Sept. 22, 2021 10:04 am ET
Investors’ deepest worries about Biogen‘s controversial Alzheimer’s therapy seemed to be coming true early Wednesday. Health-care news site STAT revealed that only around 100 patients had received Biogen‘s newly approved Alzheimer’s disease therapy Aduhelm as of Sept. 11.
Investors had expected the launch to go slowly, and Biogen (ticker: BIIB) has tried to limit expectations in recent months. Still, the STAT report suggests that the rollout is going even worse than investors had thought.